Radiation Plus Immunotherapy After Head and Neck Cancer Surgery
Treatments studied
Part of Cancer clinical trials.
This study tests whether adding immunotherapy drugs (nimotuzumab and possibly benmelstobart) to radiation therapy after head and neck cancer surgery improves outcomes. You may qualify if you've recently had surgery for squamous cell carcinoma (a common type of head and neck cancer) and have certain risk factors that suggest your cancer could return.
Summary written for real people, not researchers, by Clin2.
Who can take part
- At least 18 years old and in reasonable overall health (able to care for yourself with minimal assistance)
- Had surgery to remove head and neck squamous cell carcinoma and have at least one intermediate risk factor (like large tumor size, spread to lymph nodes, narrow surgical margins, or deep invasion)
- Cancer in the mouth, throat, or voice box; if oropharyngeal cancer, must be p16-negative (a specific test result)
- Normal or near-normal blood counts and liver function within the last 2 weeks
- Expected to live at least 6 months; willing to use contraception during the study if of childbearing age
- No active autoimmune disease, HIV infection, or recent cancer diagnosis; no prior immunotherapy or anti-EGFR treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
This Phase 2 study tests whether giving low-dose radiation before surgery—along with chemotherapy and an immunotherapy drug—can work better and be safe for treating locally advanced head and neck squamous cell cancer. It may help shrink tumors before surgery and reduce the chance of the cancer coming back.
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
This trial tests whether combining radiation therapy with immunotherapy works better than immunotherapy alone for advanced head and neck cancer that hasn't been treated before. The goal is to help your body's immune system fight the cancer more effectively.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.